New COVID Pill Shows Promise in Preventing Infection

A novel oral antiviral medication, ensitrelvir, is showing significant potential as a post-exposure treatment to prevent COVID-19 infection. Research published in the New England Journal of Medicine revealed that participants who took ensitrelvir within 72 hours of exposure were 67% less likely to develop the virus compared to those who received a placebo.

The double-blind, randomized study included over 2,000 participants. For individuals at higher risk of severe COVID-19, ensitrelvir reduced the odds of contracting the virus by 76%. This oral pill works by blocking the main protease of SARS-CoV-2, inhibiting viral replication.

While current COVID-19 vaccines are effective, ensitrelvir demonstrated a higher rate of preventing infection post-exposure. However, experts emphasize that vaccines continue to provide superior protection against severe illness and hospitalization. Both ensitrelvir and placebo groups reported similar side effect profiles.

Ensitrelvir, already approved in Japan, is currently under FDA review, with a decision expected as early as next month. If approved, it would become the only available medication for preventing COVID-19 following exposure, offering a much-needed preventative modality, particularly for those at higher risk.